InvestorsHub Logo
Followers 8
Posts 628
Boards Moderated 0
Alias Born 05/26/2021

Re: BlazingStocks post# 12064

Monday, 03/14/2022 11:14:40 AM

Monday, March 14, 2022 11:14:40 AM

Post# of 13742
Agreed!!!
… this stock has had its share of bumps in the road … but they have kept persevering and continue to work toward goal of bringing medical grade cancer fighting drugs to market ..
“These results not only met our expectations, but exceeded them,”
“While we knew that Escozine had cancer fighting therapeutic benefits, to see over 95 percent of cancer cells killed when introduced to the drug was truly groundbreaking. Cancer is one of the leading causes of death worldwide and finding an effective therapeutic is known as the holy grail of medicine. While we still have research to conduct in order to prove this drug is an effective treatment for cancer, results like these from such a credible institution will pave the way for this further exploration.”
Escozine® is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife.
Excerpt taken from;
https://www.biospace.com/article/releases/medolife-rx-announces-positive-pre-clinical-results-showing-up-to-95-percent-cancer-cell-apoptosis-with-introduction-of-lead-cancer-drug-candidate/

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.